Inhibrx Stock Price, News & Analysis (NASDAQ:INBX) $22.39 +1.62 (+7.80%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$19.86▼$22.4450-Day Range$14.50▼$22.3952-Week Range$14.31▼$32.71Volume277,479 shsAverage Volume400,877 shsMarket Capitalization$1.06 billionP/E RatioN/ADividend YieldN/APrice Target$36.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Inhibrx MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside63.0% Upside$36.50 Price TargetShort InterestBearish15.31% of Float Sold ShortDividend StrengthN/ASustainability-1.21Upright™ Environmental ScoreNews Sentiment0.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.45) to ($4.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.16 out of 5 starsMedical Sector453rd out of 954 stocksBiological Products, Except Diagnostic Industry75th out of 159 stocks 3.5 Analyst's Opinion Consensus RatingInhibrx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $36.50, Inhibrx has a forecasted upside of 63.0% from its current price of $22.39.Amount of Analyst CoverageInhibrx has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted15.31% of the float of Inhibrx has been sold short.Short Interest Ratio / Days to CoverInhibrx has a short interest ratio ("days to cover") of 12, which indicates bearish sentiment.Change versus previous monthShort interest in Inhibrx has recently increased by 5.38%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInhibrx does not currently pay a dividend.Dividend GrowthInhibrx does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInhibrx has received a 71.13% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Clinical research services for deficiency diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Inhibrx is -1.21. Previous Next 1.9 News and Social Media Coverage News SentimentInhibrx has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Inhibrx this week, compared to 1 article on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inhibrx insiders have not sold or bought any company stock.Percentage Held by Insiders22.20% of the stock of Inhibrx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.46% of the stock of Inhibrx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Inhibrx are expected to grow in the coming year, from ($4.45) to ($4.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inhibrx is -5.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inhibrx is -5.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInhibrx has a P/B Ratio of 8.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Inhibrx Stock (NASDAQ:INBX)Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio, Inc., Bristol-Myers Squibb Company, and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla, California.Read More INBX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INBX Stock News HeadlinesNovember 10, 2023 | msn.comInhibrx posts Q3 resultsNovember 10, 2023 | finanznachrichten.deInhibrx, Inc.: Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsDecember 2, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 9, 2023 | finance.yahoo.comInhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsNovember 4, 2023 | msn.comInhibrx reports initial Phase I Ewing sarcoma trial dataNovember 2, 2023 | finance.yahoo.comInhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing SarcomaSeptember 19, 2023 | finance.yahoo.comInhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and CanadaAugust 29, 2023 | marketwatch.comInhibrx Shares Rise 15% After Private Placement FinancingDecember 2, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.August 29, 2023 | finance.yahoo.comInhibrx Announces $200 Million Private Placement FinancingAugust 23, 2023 | markets.businessinsider.comJMP Securities Maintains Outperform Rating for Inhibrx: Here's What You Need To KnowAugust 23, 2023 | nasdaq.comJMP Securities Maintains Inhibrx (INBX) Outperform RecommendationAugust 23, 2023 | markets.businessinsider.comJMP Securities Reaffirms Their Buy Rating on Inhibrx (INBX)August 17, 2023 | msn.comInhibrx: INBRX-101 Developments Constructive, Market-Generated Data Not So MuchAugust 16, 2023 | markets.businessinsider.comLifeSci Capital Sticks to Their Buy Rating for Inhibrx (INBX)August 8, 2023 | finance.yahoo.comInhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsJune 27, 2023 | marketwatch.comTheft in open court: How a fight over lifesaving drugs led to accusations of brazen industrial espionageMay 30, 2023 | finance.yahoo.comInhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin DeficiencyMay 11, 2023 | msn.comJMP Securities Reiterates Inhibrx (INBX) Market Outperform RecommendationMay 9, 2023 | finanznachrichten.deInhibrx Inc.: Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsMay 8, 2023 | finance.yahoo.comInhibrx Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsMay 8, 2023 | finance.yahoo.comInhibrx, Inc. (INBX) Reports Q1 Loss, Lags Revenue EstimatesMay 4, 2023 | msn.comStrength Seen in Inhibrx, Inc. (INBX): Can Its 9.9% Jump Turn into More Strength?May 1, 2023 | nasdaq.comINBX Makes Bullish Cross Above Critical Moving AverageApril 26, 2023 | msn.comInhibrx Resumes Patient Enrollment In INBRX-109 Studies In Cancer PatientsApril 26, 2023 | finance.yahoo.comInhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist TrialsApril 13, 2023 | seekingalpha.comInhibrx: Undercovered Company With Good PotentialSee More Headlines Receive INBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inhibrx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/01/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INBX CUSIPN/A CIK1739614 Webwww.inhibrx.com Phone858-795-4220FaxN/AEmployees132Year FoundedN/APrice Target and Rating Average Stock Price Target$36.50 High Stock Price Target$46.00 Low Stock Price Target$27.00 Potential Upside/Downside+63.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($4.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-145,230,000.00 Net Margins-42,880.00% Pretax Margin-42,878.64% Return on Equity-424.05% Return on Assets-66.76% Debt Debt-to-Equity Ratio1.59 Current Ratio10.16 Quick Ratio10.16 Sales & Book Value Annual Sales$2.19 million Price / Sales483.48 Cash FlowN/A Price / Cash FlowN/A Book Value$2.74 per share Price / Book8.17Miscellaneous Outstanding Shares47,290,000Free Float36,792,000Market Cap$1.06 billion OptionableNot Optionable Beta2.72 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Mark Paul Lappe (Age 56)Founder, Chairman, President & CEO Comp: $1.02MDr. Brendan P. Eckelman Ph.D. (Age 44)Founder & Chief Scientific Officer Comp: $704kMs. Kelly Devine Deck B.S. (Age 42)CPA, M.S., Executive VP & CFO Comp: $531.17kMr. Quinn L. DeverauxFounderDr. Ashraf Amanullah (Age 55)Executive VP & Chief Technical Operations Officer Ms. Leah Pollema J.D.VP, Corporate Secretary & General CounselDr. Charbel Helaihel Pharm.D.Vice President of Marketing & Commercial PlanningMr. Jeffrey J. JensenExecutive VP & Chief Clinical Operations OfficerMr. David Matly M.B.A.Executive VP and Chief Commercial & Business Development OfficerDr. Carlos Bais Ph.D.Executive Vice President of Translational SciencesMore ExecutivesKey CompetitorsRelay TherapeuticsNASDAQ:RLAYBioCryst PharmaceuticalsNASDAQ:BCRXEditas MedicineNASDAQ:EDITApogee TherapeuticsNASDAQ:APGEKymera TherapeuticsNASDAQ:KYMRView All CompetitorsInsiders & InstitutionsWellington Management Group LLPBought 34,310 shares on 12/1/2023Ownership: 0.370%Deutsche Bank AGBought 2,156 shares on 11/24/2023Ownership: 0.034%Walleye Capital LLCBought 37,744 shares on 11/21/2023Ownership: 0.150%Tudor Investment Corp Et AlBought 21,710 shares on 11/16/2023Ownership: 0.046%Schroder Investment Management GroupSold 83,946 shares on 11/15/2023Ownership: 0.502%View All Insider TransactionsView All Institutional Transactions INBX Stock Analysis - Frequently Asked Questions Should I buy or sell Inhibrx stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inhibrx in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INBX shares. View INBX analyst ratings or view top-rated stocks. What is Inhibrx's stock price target for 2024? 3 Wall Street research analysts have issued twelve-month price targets for Inhibrx's shares. Their INBX share price targets range from $27.00 to $46.00. On average, they expect the company's share price to reach $36.50 in the next twelve months. This suggests a possible upside of 63.0% from the stock's current price. View analysts price targets for INBX or view top-rated stocks among Wall Street analysts. How have INBX shares performed in 2023? Inhibrx's stock was trading at $24.64 on January 1st, 2023. Since then, INBX shares have decreased by 9.1% and is now trading at $22.39. View the best growth stocks for 2023 here. Are investors shorting Inhibrx? Inhibrx saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 5,290,000 shares, an increase of 5.4% from the October 31st total of 5,020,000 shares. Based on an average daily trading volume, of 441,300 shares, the days-to-cover ratio is presently 12.0 days. Currently, 15.3% of the shares of the stock are sold short. View Inhibrx's Short Interest. When is Inhibrx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024. View our INBX earnings forecast. How were Inhibrx's earnings last quarter? Inhibrx, Inc. (NASDAQ:INBX) released its earnings results on Thursday, November, 9th. The company reported ($1.10) earnings per share for the quarter, missing analysts' consensus estimates of ($1.01) by $0.09. The company earned $0.12 million during the quarter. Inhibrx had a negative net margin of 42,880.00% and a negative trailing twelve-month return on equity of 424.05%. What other stocks do shareholders of Inhibrx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inhibrx investors own include Advanced Micro Devices (AMD), Trevena (TRVN), Vivint Solar (VSLR), Activision Blizzard (ATVI), Daqo New Energy (DQ), Fastly (FSLY), Innovative Industrial Properties (IIPR), Lovesac (LOVE) and Micron Technology (MU). When did Inhibrx IPO? (INBX) raised $102 million in an initial public offering (IPO) on Wednesday, August 19th 2020. The company issued 6,000,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager. Who are Inhibrx's major shareholders? Inhibrx's stock is owned by many different retail and institutional investors. Top institutional investors include RA Capital Management L.P. (9.99%), FMR LLC (3.48%), Loomis Sayles & Co. L P (2.56%), Eventide Asset Management LLC (0.99%), Northern Trust Corp (0.72%) and Schroder Investment Management Group (0.50%). Insiders that own company stock include Brendan P Eckelman, Global Investors Lp Viking, Jon Faiz Kayyem and Mark Lappe. View institutional ownership trends. How do I buy shares of Inhibrx? Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:INBX) was last updated on 12/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.